New strategies in vaccine development are urgently needed to combat emerging influenza viruses and to reduce the risk of pandemic disease surfacing. Being conserved, the M2 e protein, is a potential candidate for univ...New strategies in vaccine development are urgently needed to combat emerging influenza viruses and to reduce the risk of pandemic disease surfacing. Being conserved, the M2 e protein, is a potential candidate for universal vaccine development against influenza A viruses. Mycobacterium tuberculosis Hsp70(mHsp70) is known to cultivate the function of immunogenic antigen-presenting cells, stimulate a strong cytotoxic T lymphocyte(CTL) response, and stop the induction of tolerance. Thus, in this study, a recombinant protein from the extracellular domain of influenza A virus matrix protein 2(M2e), was fused to the C-terminus of Mycobacterium tuberculosis Hsp70(Hsp70c), to generate a vaccine candidate. Humoral immune responses, IFN-γ-producing lymphocyte, and strong CTL activity were all induced to confirm the immunogenicity of M2 e.Hsp70c(Hsp70359–610). And challenge tests showed protection against H1N1 and H9N2 strains in vaccinated groups. Finally these results demonstrates M2 e.Hsp70c fusion protein can be a candidate for a universal influenza A vaccine.展开更多
Bone morphogenetic proteins are osteoinductive factors which have gained popularity in orthopaedicsurgery and especially in spine surgery. The use of recombinant human bone morphogenetic protein-2 has been officially ...Bone morphogenetic proteins are osteoinductive factors which have gained popularity in orthopaedicsurgery and especially in spine surgery. The use of recombinant human bone morphogenetic protein-2 has been officially approved by the United States Food and Drug Administration only for single level anterior lumbar interbody fusion, nevertheless it is widely used by many surgeons with off-label indications. Despite advantages in bone formation, its use still remains a controversial issue and several complications have been described by authors who oppose their wide use.展开更多
脊柱融合是治疗脊柱结核、感染、畸形、椎间盘退行性病变脊柱疾患的有效手段,促进脊柱融合成骨率的方法之一就是使用自体骨移植,但其存在来源有限、取骨处疼痛等弊端,目前人重组骨形态发生蛋白-2(The role of recombinant human bone mo...脊柱融合是治疗脊柱结核、感染、畸形、椎间盘退行性病变脊柱疾患的有效手段,促进脊柱融合成骨率的方法之一就是使用自体骨移植,但其存在来源有限、取骨处疼痛等弊端,目前人重组骨形态发生蛋白-2(The role of recombinant human bone morphogenetic 2,rh BMP-2)负载于载体是一种理想的自体骨移植材料的替代物,广泛应用于脊柱融合术中,但近来发现了与其相关的一些副反应。本文就其在脊柱融合中的应用的安全性、有效性及相关的副反应进行综述。展开更多
目的探究重组人类骨形成蛋白-2(recombinant human bone morphogenetic protein-2,rhBMP-2)在腰椎椎间融合中应用的临床疗效。方法选取本院2018年1月至2019年6月收治的60例行腰椎退变性疾病后路减压融合术患者,按照治疗方法的不同分为A...目的探究重组人类骨形成蛋白-2(recombinant human bone morphogenetic protein-2,rhBMP-2)在腰椎椎间融合中应用的临床疗效。方法选取本院2018年1月至2019年6月收治的60例行腰椎退变性疾病后路减压融合术患者,按照治疗方法的不同分为A组和B组,每组30例。A组采用rhBMP-2和自体骨复合植骨治疗,B组采用传统自体骨植骨与椎间融合器治疗,比较两组不同时间点椎间隙高度、腰腿部疼痛视觉模拟评分(VAS)、Oswestry功能障碍指数(ODI)评分、植骨融合及并发症发生率。结果术后,两组各时间点VAS、ODI评分均低于术前,椎间隙高度均高于术前(P<0.05),但组间比较差异无统计学意义;术后3个月,A组植骨融合率高于B组(P<0.05),术后6、12个月,两组植骨融合率比较差异无统计学意义。两组无一例术后出现相关并发症。结论rhBMP-2应用于退变性腰椎疾病椎间融合中可提高近期随访融合率,减少手术融合失败率,远期疗效与自体骨相当,应用rhBMP-2骨诱导效果好、融合快、成功率高,且可避免有创取材,具有较高的临床应用价值。展开更多
背景:重组人骨形态发生蛋白2(recombinant human bone morphogenetic protein-2,rhBMP-2)联合自体骨行椎间植骨融合术治疗腰椎滑脱、椎管狭窄、椎间盘突出等脊柱退行性变疾病的疗效和安全性已经得到认可,但对于治疗脊柱结核等脊柱感染...背景:重组人骨形态发生蛋白2(recombinant human bone morphogenetic protein-2,rhBMP-2)联合自体骨行椎间植骨融合术治疗腰椎滑脱、椎管狭窄、椎间盘突出等脊柱退行性变疾病的疗效和安全性已经得到认可,但对于治疗脊柱结核等脊柱感染性疾病的疗效和安全性少有临床研究。目的:评价rhBMP-2联合自体骨行椎间植骨融合术对脊柱结核的临床疗效及其安全性。方法:回顾性分析2010年11月至2018年5月广州中医药大学第一附属医院收治的胸腰椎结核患者的临床资料,所有患者均采用后路经椎弓根螺钉内固定+植骨融合术,根据植骨时是否使用rhBMP-2将其分为2组,试验组33例采用1 mg rhBMP-2联合自体骨植入大小适宜的支撑体中,对照组35例单纯用自体骨植入支撑体。术后随访1年以上,并对术前、术后疼痛目测类比评分、脊髓损伤ASIA分级、围术期并发症以及融合率进行统计学分析。研究通过广州中医药大学第一附属医院伦理委员会的批准,患者对治疗方案均知情同意。结果与结论:①所有患者均完成1年以上的随访,随访中未发现内固定断裂移动和椎体的明显塌陷;②两组手术时间、术中出血量、住院时间、围术期并发症比例差异无显著性意义(P>0.05);③两组术后1周和术后1年的目测类比评分、ASIA分级与术前相比,有显著改善(P<0.05),但两组之间对比差异无显著性意义(P>0.05);④在融合率方面,试验组术后6个月的融合率明显高于对照组(P<0.05),然而,两组术后1年的融合率比较却无统计学差异(P>0.05)。提示:rhBMP-2联合自体骨行植骨融合术治疗胸腰椎结核能在短期内加快骨性融合,具有良好的疗效和安全性。展开更多
文摘New strategies in vaccine development are urgently needed to combat emerging influenza viruses and to reduce the risk of pandemic disease surfacing. Being conserved, the M2 e protein, is a potential candidate for universal vaccine development against influenza A viruses. Mycobacterium tuberculosis Hsp70(mHsp70) is known to cultivate the function of immunogenic antigen-presenting cells, stimulate a strong cytotoxic T lymphocyte(CTL) response, and stop the induction of tolerance. Thus, in this study, a recombinant protein from the extracellular domain of influenza A virus matrix protein 2(M2e), was fused to the C-terminus of Mycobacterium tuberculosis Hsp70(Hsp70c), to generate a vaccine candidate. Humoral immune responses, IFN-γ-producing lymphocyte, and strong CTL activity were all induced to confirm the immunogenicity of M2 e.Hsp70c(Hsp70359–610). And challenge tests showed protection against H1N1 and H9N2 strains in vaccinated groups. Finally these results demonstrates M2 e.Hsp70c fusion protein can be a candidate for a universal influenza A vaccine.
文摘Bone morphogenetic proteins are osteoinductive factors which have gained popularity in orthopaedicsurgery and especially in spine surgery. The use of recombinant human bone morphogenetic protein-2 has been officially approved by the United States Food and Drug Administration only for single level anterior lumbar interbody fusion, nevertheless it is widely used by many surgeons with off-label indications. Despite advantages in bone formation, its use still remains a controversial issue and several complications have been described by authors who oppose their wide use.
文摘脊柱融合是治疗脊柱结核、感染、畸形、椎间盘退行性病变脊柱疾患的有效手段,促进脊柱融合成骨率的方法之一就是使用自体骨移植,但其存在来源有限、取骨处疼痛等弊端,目前人重组骨形态发生蛋白-2(The role of recombinant human bone morphogenetic 2,rh BMP-2)负载于载体是一种理想的自体骨移植材料的替代物,广泛应用于脊柱融合术中,但近来发现了与其相关的一些副反应。本文就其在脊柱融合中的应用的安全性、有效性及相关的副反应进行综述。
文摘目的探究重组人类骨形成蛋白-2(recombinant human bone morphogenetic protein-2,rhBMP-2)在腰椎椎间融合中应用的临床疗效。方法选取本院2018年1月至2019年6月收治的60例行腰椎退变性疾病后路减压融合术患者,按照治疗方法的不同分为A组和B组,每组30例。A组采用rhBMP-2和自体骨复合植骨治疗,B组采用传统自体骨植骨与椎间融合器治疗,比较两组不同时间点椎间隙高度、腰腿部疼痛视觉模拟评分(VAS)、Oswestry功能障碍指数(ODI)评分、植骨融合及并发症发生率。结果术后,两组各时间点VAS、ODI评分均低于术前,椎间隙高度均高于术前(P<0.05),但组间比较差异无统计学意义;术后3个月,A组植骨融合率高于B组(P<0.05),术后6、12个月,两组植骨融合率比较差异无统计学意义。两组无一例术后出现相关并发症。结论rhBMP-2应用于退变性腰椎疾病椎间融合中可提高近期随访融合率,减少手术融合失败率,远期疗效与自体骨相当,应用rhBMP-2骨诱导效果好、融合快、成功率高,且可避免有创取材,具有较高的临床应用价值。
文摘背景:重组人骨形态发生蛋白2(recombinant human bone morphogenetic protein-2,rhBMP-2)联合自体骨行椎间植骨融合术治疗腰椎滑脱、椎管狭窄、椎间盘突出等脊柱退行性变疾病的疗效和安全性已经得到认可,但对于治疗脊柱结核等脊柱感染性疾病的疗效和安全性少有临床研究。目的:评价rhBMP-2联合自体骨行椎间植骨融合术对脊柱结核的临床疗效及其安全性。方法:回顾性分析2010年11月至2018年5月广州中医药大学第一附属医院收治的胸腰椎结核患者的临床资料,所有患者均采用后路经椎弓根螺钉内固定+植骨融合术,根据植骨时是否使用rhBMP-2将其分为2组,试验组33例采用1 mg rhBMP-2联合自体骨植入大小适宜的支撑体中,对照组35例单纯用自体骨植入支撑体。术后随访1年以上,并对术前、术后疼痛目测类比评分、脊髓损伤ASIA分级、围术期并发症以及融合率进行统计学分析。研究通过广州中医药大学第一附属医院伦理委员会的批准,患者对治疗方案均知情同意。结果与结论:①所有患者均完成1年以上的随访,随访中未发现内固定断裂移动和椎体的明显塌陷;②两组手术时间、术中出血量、住院时间、围术期并发症比例差异无显著性意义(P>0.05);③两组术后1周和术后1年的目测类比评分、ASIA分级与术前相比,有显著改善(P<0.05),但两组之间对比差异无显著性意义(P>0.05);④在融合率方面,试验组术后6个月的融合率明显高于对照组(P<0.05),然而,两组术后1年的融合率比较却无统计学差异(P>0.05)。提示:rhBMP-2联合自体骨行植骨融合术治疗胸腰椎结核能在短期内加快骨性融合,具有良好的疗效和安全性。
